XOMA Co. (NASDAQ:XOMA) Given Consensus Recommendation of “Hold” by Analysts

Shares of XOMA Co. (NASDAQ:XOMAGet Rating) have earned an average recommendation of “Hold” from the six brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $49.00.

A number of research analysts recently commented on the company. StockNews.com downgraded XOMA from a “buy” rating to a “hold” rating in a research note on Friday, April 22nd. Zacks Investment Research downgraded XOMA from a “hold” rating to a “strong sell” rating in a research note on Saturday, January 8th. Finally, TheStreet raised XOMA from a “c-” rating to a “b-” rating in a research note on Friday, April 1st.

In other news, CEO James R. Neal sold 50,000 shares of the business’s stock in a transaction dated Monday, March 21st. The stock was sold at an average price of $29.00, for a total transaction of $1,450,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Thomas M. Burns sold 2,339 shares of the business’s stock in a transaction dated Tuesday, March 22nd. The stock was sold at an average price of $30.02, for a total value of $70,216.78. The disclosure for this sale can be found here. In the last three months, insiders have sold 53,450 shares of company stock valued at $1,553,569. Insiders own 9.89% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Geneos Wealth Management Inc. bought a new stake in XOMA in the third quarter valued at approximately $25,000. Citigroup Inc. boosted its holdings in XOMA by 118.0% in the fourth quarter. Citigroup Inc. now owns 1,528 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 827 shares during the last quarter. BNP Paribas Arbitrage SA boosted its holdings in XOMA by 138.5% in the third quarter. BNP Paribas Arbitrage SA now owns 1,436 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 834 shares during the last quarter. Barclays PLC boosted its holdings in XOMA by 222.0% in the third quarter. Barclays PLC now owns 2,463 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 1,698 shares during the last quarter. Finally, Morgan Stanley boosted its holdings in XOMA by 181.6% in the second quarter. Morgan Stanley now owns 2,630 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 1,696 shares during the last quarter. Institutional investors and hedge funds own 56.14% of the company’s stock.

XOMA stock opened at $19.23 on Friday. The company has a market cap of $219.15 million, a PE ratio of 128.21 and a beta of 0.89. The business has a 50-day simple moving average of $24.92 and a 200 day simple moving average of $23.28. XOMA has a 52 week low of $18.82 and a 52 week high of $39.49.

XOMA (NASDAQ:XOMAGet Rating) last posted its quarterly earnings results on Tuesday, March 8th. The biotechnology company reported $1.67 EPS for the quarter, missing the Zacks’ consensus estimate of $2.27 by ($0.60). The company had revenue of $35.94 million during the quarter, compared to analyst estimates of $34.84 million. XOMA had a net margin of 14.57% and a return on equity of 4.93%.

About XOMA (Get Rating)

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.

Read More

Want More Great Investing Ideas?

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.